Kaare Meier

Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome

Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

Standard

Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome. / Poulsen, Dennis Møgeltoft; Sørensen, Jens Christian Hedemann; Blichfeldt-Eckhardt, Morten Rune; Gulisano, Helga Angela ; Meier, Kaare.

2019. Abstract from Nordic Neuromodulation Society's 6th Annual Meeting, Aarhus, Denmark.

Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

Harvard

Poulsen, DM, Sørensen, JCH, Blichfeldt-Eckhardt, MR, Gulisano, HA & Meier, K 2019, 'Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome', Nordic Neuromodulation Society's 6th Annual Meeting, Aarhus, Denmark, 02/10/2019 - 04/10/2019.

APA

Poulsen, D. M., Sørensen, J. C. H., Blichfeldt-Eckhardt, M. R., Gulisano, H. A., & Meier, K. (2019). Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome. Abstract from Nordic Neuromodulation Society's 6th Annual Meeting, Aarhus, Denmark.

CBE

Poulsen DM, Sørensen JCH, Blichfeldt-Eckhardt MR, Gulisano HA, Meier K. 2019. Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome. Abstract from Nordic Neuromodulation Society's 6th Annual Meeting, Aarhus, Denmark.

MLA

Poulsen, Dennis Møgeltoft et al. Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome. Nordic Neuromodulation Society's 6th Annual Meeting, 02 Oct 2019, Aarhus, Denmark, Conference abstract for conference, 2019.

Vancouver

Poulsen DM, Sørensen JCH, Blichfeldt-Eckhardt MR, Gulisano HA, Meier K. Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome. 2019. Abstract from Nordic Neuromodulation Society's 6th Annual Meeting, Aarhus, Denmark.

Author

Poulsen, Dennis Møgeltoft ; Sørensen, Jens Christian Hedemann ; Blichfeldt-Eckhardt, Morten Rune ; Gulisano, Helga Angela ; Meier, Kaare. / Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome. Abstract from Nordic Neuromodulation Society's 6th Annual Meeting, Aarhus, Denmark.

Bibtex

@conference{62abe1b6440042fe8713d5db36e71fc6,
title = "Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome",
abstract = "Introduction:It is well documented that opioid usage leads to increased mortality and morbidity and that certain patients may develop opioid addiction. At the same time, the clinical outcome of spinal cord stimulation (SCS) shows very large individual variation: Some patients experience almost complete pain relief, while others have no beneficial effect at all and may end up being explanted. Recently published data shows opioid consumption prior to initiation of SCS may be associated with an unfavorable treatment outcome. We investigated whether opioid usage prior to initiation of SCS was associated with:   1)Risk of permanent explantation as a proxy of treatment failure.   2)Latest rating on Patients{\textquoteright} Global Impression of Change (PGIC) scale.Methods:We used data from the Neurizon Neuromodulation Database containing detailed records of patients implanted with a device for SCS at Aarhus, Odense or Aalborg University Hospital, Denmark. From the database records we identified patients with a preimplantation medicine registration and subsequently their current treatment status (active stimulation/permanently explanted) and latest PGIC rating.Patients were grouped according to preimplantation opioid use (Y/N) and oral morphine equivalent values (OME) were calculated for opioid users.The relationships between preimplantation opioid use, current treatment status and latest PGIC rating were evaluated with Χ2-tests. Associations between preimplantation OME values, current treatment status and latest PGIC rating were assessed by a t-test and a one-way ANOVA of log transformed data, respectively.Results:A total of 248 patients had a preimplantation medicine registration – all of these had a registration of currents treatment status and 190 patients had a PGIC rating. The presence of opioid usage (Y/N) prior to initiation of SCS was not associated with current treatment status (p-value =0.58) or latest PGIC rating (p-value = 0.39). Among opioid users median preimplantation OME values did not differ between groups of current treatment status (p-value = 0.20) or PGIC rating (p-value = 0.48).Conclusion:The presence of opioid usage (Y/N) prior to implantation with a device for SCS was not associated with risk of permanent explantation or latest PGIC rating. Among patients using opioids prior to implantation, the dosage of opioids expressed in terms of OME values was not associated with risk of being permanently explanted or latest PGIC rating.",
author = "Poulsen, {Dennis M{\o}geltoft} and S{\o}rensen, {Jens Christian Hedemann} and Blichfeldt-Eckhardt, {Morten Rune} and Gulisano, {Helga Angela} and Kaare Meier",
year = "2019",
month = oct,
day = "2",
language = "English",
note = "null ; Conference date: 02-10-2019 Through 04-10-2019",

}

RIS

TY - ABST

T1 - Opioid Consumption Prior to Initiation of Spinal Cord Stimulation Does Not Predict Treatment Outcome

AU - Poulsen, Dennis Møgeltoft

AU - Sørensen, Jens Christian Hedemann

AU - Blichfeldt-Eckhardt, Morten Rune

AU - Gulisano, Helga Angela

AU - Meier, Kaare

PY - 2019/10/2

Y1 - 2019/10/2

N2 - Introduction:It is well documented that opioid usage leads to increased mortality and morbidity and that certain patients may develop opioid addiction. At the same time, the clinical outcome of spinal cord stimulation (SCS) shows very large individual variation: Some patients experience almost complete pain relief, while others have no beneficial effect at all and may end up being explanted. Recently published data shows opioid consumption prior to initiation of SCS may be associated with an unfavorable treatment outcome. We investigated whether opioid usage prior to initiation of SCS was associated with:   1)Risk of permanent explantation as a proxy of treatment failure.   2)Latest rating on Patients’ Global Impression of Change (PGIC) scale.Methods:We used data from the Neurizon Neuromodulation Database containing detailed records of patients implanted with a device for SCS at Aarhus, Odense or Aalborg University Hospital, Denmark. From the database records we identified patients with a preimplantation medicine registration and subsequently their current treatment status (active stimulation/permanently explanted) and latest PGIC rating.Patients were grouped according to preimplantation opioid use (Y/N) and oral morphine equivalent values (OME) were calculated for opioid users.The relationships between preimplantation opioid use, current treatment status and latest PGIC rating were evaluated with Χ2-tests. Associations between preimplantation OME values, current treatment status and latest PGIC rating were assessed by a t-test and a one-way ANOVA of log transformed data, respectively.Results:A total of 248 patients had a preimplantation medicine registration – all of these had a registration of currents treatment status and 190 patients had a PGIC rating. The presence of opioid usage (Y/N) prior to initiation of SCS was not associated with current treatment status (p-value =0.58) or latest PGIC rating (p-value = 0.39). Among opioid users median preimplantation OME values did not differ between groups of current treatment status (p-value = 0.20) or PGIC rating (p-value = 0.48).Conclusion:The presence of opioid usage (Y/N) prior to implantation with a device for SCS was not associated with risk of permanent explantation or latest PGIC rating. Among patients using opioids prior to implantation, the dosage of opioids expressed in terms of OME values was not associated with risk of being permanently explanted or latest PGIC rating.

AB - Introduction:It is well documented that opioid usage leads to increased mortality and morbidity and that certain patients may develop opioid addiction. At the same time, the clinical outcome of spinal cord stimulation (SCS) shows very large individual variation: Some patients experience almost complete pain relief, while others have no beneficial effect at all and may end up being explanted. Recently published data shows opioid consumption prior to initiation of SCS may be associated with an unfavorable treatment outcome. We investigated whether opioid usage prior to initiation of SCS was associated with:   1)Risk of permanent explantation as a proxy of treatment failure.   2)Latest rating on Patients’ Global Impression of Change (PGIC) scale.Methods:We used data from the Neurizon Neuromodulation Database containing detailed records of patients implanted with a device for SCS at Aarhus, Odense or Aalborg University Hospital, Denmark. From the database records we identified patients with a preimplantation medicine registration and subsequently their current treatment status (active stimulation/permanently explanted) and latest PGIC rating.Patients were grouped according to preimplantation opioid use (Y/N) and oral morphine equivalent values (OME) were calculated for opioid users.The relationships between preimplantation opioid use, current treatment status and latest PGIC rating were evaluated with Χ2-tests. Associations between preimplantation OME values, current treatment status and latest PGIC rating were assessed by a t-test and a one-way ANOVA of log transformed data, respectively.Results:A total of 248 patients had a preimplantation medicine registration – all of these had a registration of currents treatment status and 190 patients had a PGIC rating. The presence of opioid usage (Y/N) prior to initiation of SCS was not associated with current treatment status (p-value =0.58) or latest PGIC rating (p-value = 0.39). Among opioid users median preimplantation OME values did not differ between groups of current treatment status (p-value = 0.20) or PGIC rating (p-value = 0.48).Conclusion:The presence of opioid usage (Y/N) prior to implantation with a device for SCS was not associated with risk of permanent explantation or latest PGIC rating. Among patients using opioids prior to implantation, the dosage of opioids expressed in terms of OME values was not associated with risk of being permanently explanted or latest PGIC rating.

M3 - Conference abstract for conference

Y2 - 2 October 2019 through 4 October 2019

ER -